[1]
Maeda Y, O'Connell PR, Lehur PA, Matzel KE, Laurberg S, European SNS Bowel Study Group. Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2015 Apr:17(4):O74-87. doi: 10.1111/codi.12905. Epub
[PubMed PMID: 25603960]
Level 3 (low-level) evidence
[2]
Tanagho EA, Schmidt RA. Bladder pacemaker: scientific basis and clinical future. Urology. 1982 Dec:20(6):614-9
[PubMed PMID: 7179629]
[3]
Hetzer FH. Fifteen years of sacral nerve stimulation: from an open procedure to a minimally invasive technique. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2011 Mar:13 Suppl 2():1-4. doi: 10.1111/j.1463-1318.2010.02517.x. Epub
[PubMed PMID: 21284794]
[4]
De Wachter S, Knowles CH, Elterman DS, Kennelly MJ, Lehur PA, Matzel KE, Engelberg S, Van Kerrebroeck PEV. New Technologies and Applications in Sacral Neuromodulation: An Update. Advances in therapy. 2020 Feb:37(2):637-643. doi: 10.1007/s12325-019-01205-z. Epub 2019 Dec 24
[PubMed PMID: 31875299]
Level 3 (low-level) evidence
[5]
White N, Iglesia CB. Overactive Bladder. Obstetrics and gynecology clinics of North America. 2016 Mar:43(1):59-68. doi: 10.1016/j.ogc.2015.10.002. Epub
[PubMed PMID: 26880508]
[6]
Rashid TG, Ockrim JL. Male incontinence: onabotulinum toxin A and sacral nerve stimulation. Current opinion in urology. 2013 Nov:23(6):545-51. doi: 10.1097/01.MOU.0000434594.87575.26. Epub
[PubMed PMID: 24080810]
Level 3 (low-level) evidence
[8]
Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Bennett J, Zylstra S, Berg KC, Kan F, Irwin CP. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourology and urodynamics. 2015 Mar:34(3):224-30. doi: 10.1002/nau.22544. Epub 2014 Jan 10
[PubMed PMID: 24415559]
Level 2 (mid-level) evidence
[9]
Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Bennett J, Zylstra S, Kan F, Thiery E. Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation. Urology. 2016 Aug:94():57-63. doi: 10.1016/j.urology.2016.04.024. Epub 2016 Apr 27
[PubMed PMID: 27131966]
Level 2 (mid-level) evidence
[10]
Kessler TM, Fowler CJ. Sacral neuromodulation for urinary retention. Nature clinical practice. Urology. 2008 Dec:5(12):657-66. doi: 10.1038/ncpuro1251. Epub 2008 Nov 11
[PubMed PMID: 19002127]
[11]
Elkelini MS, Abuzgaya A, Hassouna MM. Mechanisms of action of sacral neuromodulation. International urogynecology journal. 2010 Dec:21 Suppl 2():S439-46. doi: 10.1007/s00192-010-1273-3. Epub
[PubMed PMID: 20972548]
[12]
Chapple CR, Wein AJ, Abrams P, Dmochowski RR, Giuliano F, Kaplan SA, McVary KT, Roehrborn CG. Lower urinary tract symptoms revisited: a broader clinical perspective. European urology. 2008 Sep:54(3):563-9. doi: 10.1016/j.eururo.2008.03.109. Epub 2008 Apr 8
[PubMed PMID: 18423969]
Level 3 (low-level) evidence
[13]
Gaitonde S, Malik RD, Christie AL, Zimmern PE. Bethanechol: Is it still being prescribed for bladder dysfunction in women? International journal of clinical practice. 2019 Aug:73(8):e13248. doi: 10.1111/ijcp.13248. Epub 2018 Aug 15
[PubMed PMID: 30112787]
[14]
Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. British journal of pharmacology. 2006 Feb:147 Suppl 2(Suppl 2):S88-119
[PubMed PMID: 16465187]
[15]
Tachikawa K, Kyoda Y, Fukuta F, Kobayashi K, Masumori N. Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01. Lower urinary tract symptoms. 2022 Mar:14(2):109-116. doi: 10.1111/luts.12417. Epub 2021 Oct 28
[PubMed PMID: 34713579]
[16]
Frankel J, Staskin D, Varano S, Kennelly MJ, Jankowich RA, Haag-Molkenteller C. An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder. Therapeutics and clinical risk management. 2022:18():171-182. doi: 10.2147/TCRM.S310371. Epub 2022 Mar 3
[PubMed PMID: 35264853]
[17]
Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nature reviews. Neuroscience. 2008 Jun:9(6):453-66. doi: 10.1038/nrn2401. Epub
[PubMed PMID: 18490916]
[18]
Bajwa A, Emmanuel A. The physiology of continence and evacuation. Best practice & research. Clinical gastroenterology. 2009:23(4):477-85. doi: 10.1016/j.bpg.2009.06.002. Epub
[PubMed PMID: 19647684]
[19]
Sultan AH, Kamm MA, Hudson CN, Thomas JM, Bartram CI. Anal-sphincter disruption during vaginal delivery. The New England journal of medicine. 1993 Dec 23:329(26):1905-11
[PubMed PMID: 8247054]
[20]
Meurette G, Siproudhis L, Leroi AM, Damon H, Urs Josef Keller D, Faucheron JL, French Faecal Registry Study Group. Sacral neuromodulation with the InterStim™ system for faecal incontinence: results from a prospective French multicentre observational study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2021 Jun:23(6):1463-1473. doi: 10.1111/codi.15507. Epub 2021 Mar 12
[PubMed PMID: 33387373]
Level 2 (mid-level) evidence
[21]
Russo A, Sun WM, Sattawatthamrong Y, Fraser R, Horowitz M, Andrews JM, Read NW. Acute hyperglycaemia affects anorectal motor and sensory function in normal subjects. Gut. 1997 Oct:41(4):494-9
[PubMed PMID: 9391248]
[22]
Sun WM, Read NW, Prior A, Daly JA, Cheah SK, Grundy D. Sensory and motor responses to rectal distention vary according to rate and pattern of balloon inflation. Gastroenterology. 1990 Oct:99(4):1008-15
[PubMed PMID: 2394323]
[23]
Broens P, Vanbeckevoort D, Bellon E, Penninckx F. Combined radiologic and manometric study of rectal filling sensation. Diseases of the colon and rectum. 2002 Aug:45(8):1016-22
[PubMed PMID: 12195184]
[24]
Lotze M, Wietek B, Birbaumer N, Ehrhardt J, Grodd W, Enck P. Cerebral activation during anal and rectal stimulation. NeuroImage. 2001 Nov:14(5):1027-34
[PubMed PMID: 11697934]
[25]
Bharucha AE. Pelvic floor: anatomy and function. Neurogastroenterology and motility. 2006 Jul:18(7):507-19
[PubMed PMID: 16771766]
[26]
PORTER NH. A physiological study of the pelvic floor in rectal prolapse. Annals of the Royal College of Surgeons of England. 1962 Dec:31(6):379-404
[PubMed PMID: 13985573]
[27]
Enck P, Hinninghofen H, Merletti R, Azpiroz F. The external anal sphincter and the role of surface electromyography. Neurogastroenterology and motility. 2005 Jun:17 Suppl 1():60-7
[PubMed PMID: 15836456]
[28]
Shafik A, el-Sibai O. Rectal inhibition by inferior rectal nerve stimulation in dogs: recognition of a new reflex--the 'voluntary anorectal inhibition reflex'. European journal of gastroenterology & hepatology. 2001 Apr:13(4):413-8
[PubMed PMID: 11338072]
[29]
Yoshimura N. Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Progress in neurobiology. 1999 Apr:57(6):583-606
[PubMed PMID: 10221783]
[30]
Wang Y, Hassouna MM. Neuromodulation reduces c-fos gene expression in spinalized rats: a double-blind randomized study. The Journal of urology. 2000 Jun:163(6):1966-70
[PubMed PMID: 10799240]
Level 1 (high-level) evidence
[31]
Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. The Urologic clinics of North America. 2005 Feb:32(1):11-8
[PubMed PMID: 15698871]
[32]
Aboseif S, Tamaddon K, Chalfin S, Freedman S, Mourad MS, Chang JH, Kaptein JS. Sacral neuromodulation in functional urinary retention: an effective way to restore voiding. BJU international. 2002 Nov:90(7):662-5
[PubMed PMID: 12410743]
[33]
Pang D, Liao L, Chen G, Wang Y. Sacral Neuromodulation Improves Abnormal Prefrontal Brain Activity in Patients with Overactive Bladder: A Possible Central Mechanism. The Journal of urology. 2022 Jun:207(6):1256-1267. doi: 10.1097/JU.0000000000002445. Epub 2022 Jan 24
[PubMed PMID: 35072489]
[34]
Janssen PTJ, Komen N, Melenhorst J, Bouvy ND, Jahanshahi A, Temel Y, Breukink SO. Sacral Neuromodulation for Fecal Incontinence: A Review of the Central Mechanisms of Action. Journal of clinical gastroenterology. 2017 Sep:51(8):669-676. doi: 10.1097/MCG.0000000000000850. Epub
[PubMed PMID: 28723864]
[35]
Gourcerol G, Vitton V, Leroi AM, Michot F, Abysique A, Bouvier M. How sacral nerve stimulation works in patients with faecal incontinence. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2011 Aug:13(8):e203-11. doi: 10.1111/j.1463-1318.2011.02623.x. Epub
[PubMed PMID: 21689312]
[36]
Duchalais E, Drissi F, Delestre M, Wyart V, Lehur PA, Meurette G. Long-term results of sacral neuromodulation for the treatment of anorectal diseases. Journal of visceral surgery. 2022 Dec:159(6):463-470. doi: 10.1016/j.jviscsurg.2021.09.007. Epub 2021 Nov 1
[PubMed PMID: 34736877]
[37]
Martin S, Zillioux J, Goldman HB. Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review. Neurourology and urodynamics. 2022 Apr:41(4):955-961. doi: 10.1002/nau.24900. Epub 2022 Mar 3
[PubMed PMID: 35238421]
Level 2 (mid-level) evidence
[38]
Wald A. Diagnosis and Management of Fecal Incontinence. Current gastroenterology reports. 2018 Mar 26:20(3):9. doi: 10.1007/s11894-018-0614-0. Epub 2018 Mar 26
[PubMed PMID: 29582182]
[39]
Erol B, Danacioglu YO, Peters KM. Current advances in neuromodulation techniques in urology practices: A review of literature. Turkish journal of urology. 2021 Sep:47(5):375-385. doi: 10.5152/tud.2021.21152. Epub
[PubMed PMID: 35118977]
Level 3 (low-level) evidence
[40]
Šlauf P, Vobořil R. Sacral neuromodulation for faecal incontinence - 10 years experience and long-term outcomes of a specialized centre. Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti. 2021 Winter:100(10):475-483. doi: 10.33699/PIS.2021.100.10.475-483. Epub
[PubMed PMID: 35021838]
[41]
Luo C, Wei D, Pang K, Mei L, Chen Y, Niu X. Is percutaneous tibial nerve stimulation (PTNS) effective for fecal incontinence (FI) in adults compared with sham electrical stimulation? A meta-analysis. Techniques in coloproctology. 2024 Feb 24:28(1):37. doi: 10.1007/s10151-024-02910-w. Epub 2024 Feb 24
[PubMed PMID: 38401006]
Level 1 (high-level) evidence
[42]
Smith A, Bevan D, Douglas HR, James D. Management of urinary incontinence in women: summary of updated NICE guidance. BMJ (Clinical research ed.). 2013 Sep 10:347():f5170. doi: 10.1136/bmj.f5170. Epub 2013 Sep 10
[PubMed PMID: 24021756]
[43]
Das AK, White MD, Longhurst PA. Sacral nerve stimulation for the management of voiding dysfunction. Reviews in urology. 2000 Winter:2(1):43-60
[PubMed PMID: 16985735]
[44]
Ginsberg DA, Boone TB, Cameron AP, Gousse A, Kaufman MR, Keays E, Kennelly MJ, Lemack GE, Rovner ES, Souter LH, Yang CC, Kraus SR. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up. The Journal of urology. 2021 Nov:206(5):1106-1113. doi: 10.1097/JU.0000000000002239. Epub 2021 Sep 8
[PubMed PMID: 34495688]
[45]
Butrick CW. Patient selection for sacral nerve stimulation. International urogynecology journal. 2010 Dec:21 Suppl 2():S447-51. doi: 10.1007/s00192-010-1274-2. Epub
[PubMed PMID: 20972547]
[46]
Wöllner J, Hampel C, Kessler TM. Surgery Illustrated – surgical atlas sacral neuromodulation. BJU international. 2012 Jul:110(1):146-59. doi: 10.1111/j.1464-410X.2012.10906.x. Epub
[PubMed PMID: 22691023]
[47]
Sayed D, Chakravarthy K, Amirdelfan K, Kalia H, Meacham K, Shirvalkar P, Falowski S, Petersen E, Hagedorn JM, Pope J, Leever J, ASPN MRI Compatibility Working Group, Deer T. A Comprehensive Practice Guideline for Magnetic Resonance Imaging Compatibility in Implanted Neuromodulation Devices. Neuromodulation : journal of the International Neuromodulation Society. 2020 Oct:23(7):893-911. doi: 10.1111/ner.13233. Epub 2020 Aug 18
[PubMed PMID: 32809275]
Level 1 (high-level) evidence
[48]
Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology. 2005 Oct:66(4):746-50
[PubMed PMID: 16230129]
[49]
Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourology and urodynamics. 2008:27(1):28-33
[PubMed PMID: 17563110]
[50]
Zbar AP. Sacral neuromodulation and peripheral nerve stimulation in patients with anal incontinence: an overview of techniques, complications and troubleshooting. Gastroenterology report. 2014 May:2(2):112-20. doi: 10.1093/gastro/gou015. Epub 2014 Apr 10
[PubMed PMID: 24759349]
Level 3 (low-level) evidence
[51]
Liberman D, Ehlert MJ, Siegel SW. Sacral Neuromodulation in Urological Practice. Urology. 2017 Jan:99():14-22. doi: 10.1016/j.urology.2016.06.004. Epub 2016 Jun 11
[PubMed PMID: 27298200]
[52]
Hendrickson WK, Amundsen CL. Sacral neuromodulation: troubleshooting needle placement. International urogynecology journal. 2021 Sep:32(9):2549-2551. doi: 10.1007/s00192-020-04614-9. Epub 2021 Jan 8
[PubMed PMID: 33416966]
[53]
Rosen A, Elias S, Ganer Herman H, Condrea A, Ginath S. Computed Tomography-Guided Placement of Sacral Electrodes. The Israel Medical Association journal : IMAJ. 2021 Dec:23(12):773-776
[PubMed PMID: 34954915]
[54]
Sampogna G, Montanari E, Spinelli M. Computer-Assisted Lead Placement for Peripheral Nerve Evaluation Test in a Candidate for Sacral Neuromodulation. International neurourology journal. 2020 Dec:24(4):382-386. doi: 10.5213/inj.2040096.048. Epub 2020 Dec 31
[PubMed PMID: 33401360]
[55]
Tilborghs S, De Wachter S. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects. Expert review of medical devices. 2022 Feb:19(2):161-187. doi: 10.1080/17434440.2022.2032655. Epub 2022 Feb 6
[PubMed PMID: 35061951]
Level 1 (high-level) evidence
[56]
Tilborghs S, Van de Borne S, Vaganée D, De Win G, De Wachter S. The Influence of Electrode Configuration Changes on the Sensory and Motor Response During (Re)Programming in Sacral Neuromodulation. Neuromodulation : journal of the International Neuromodulation Society. 2022 Dec:25(8):1173-1179. doi: 10.1016/j.neurom.2021.09.001. Epub 2021 Dec 18
[PubMed PMID: 35088741]
[57]
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama á Nijholt AA, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM, Cappellano F, Elhilali MM, Milam DF, Das AK, Dijkema HE, van den Hombergh U. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. The Journal of urology. 2007 Nov:178(5):2029-34
[PubMed PMID: 17869298]
[58]
Meng L, Yan Z, Wang X, Zhang Y, Zhu Z, Zhu W, Ling Q, Sun X, Gu Y, Lv J, Li Y. Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: A multi-center retrospective cohort study from China. International journal of surgery (London, England). 2024 Mar 4:():. doi: 10.1097/JS9.0000000000001302. Epub 2024 Mar 4
[PubMed PMID: 38445489]
Level 2 (mid-level) evidence
[59]
Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Zylstra S, Kan F, Berg KC. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. The Journal of urology. 2018 Jan:199(1):229-236. doi: 10.1016/j.juro.2017.07.010. Epub 2017 Jul 11
[PubMed PMID: 28709886]
Level 2 (mid-level) evidence
[60]
Coolen RL, Groen J, Blok B. Electrical stimulation in the treatment of bladder dysfunction: technology update. Medical devices (Auckland, N.Z.). 2019:12():337-345. doi: 10.2147/MDER.S179898. Epub 2019 Sep 11
[PubMed PMID: 31572023]
[61]
Powell CR. Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function. Current urology reports. 2018 Aug 20:19(10):86. doi: 10.1007/s11934-018-0837-5. Epub 2018 Aug 20
[PubMed PMID: 30128939]
[62]
Rueb J, Fascelli M, Goldman HB, Vasavada S, Rackley R, Moore C, Gill B. The role of pulse width manipulation compared to program changes alone for unsatisfactory sacral neuromodulation therapy: A retrospective matched-cohort analysis. Neurourology and urodynamics. 2021 Jan:40(1):522-528. doi: 10.1002/nau.24593. Epub 2020 Dec 11
[PubMed PMID: 33305838]
[63]
Chen S, Wang S, Gao Y, Lu X, Yan J, Xuan L, Wang S. Bilateral electrical pudendal nerve stimulation as additional therapy for lower urinary tract dysfunction when stage II sacral neuromodulator fails: a case report. BMC urology. 2021 Mar 10:21(1):37. doi: 10.1186/s12894-021-00808-5. Epub 2021 Mar 10
[PubMed PMID: 33691669]
Level 3 (low-level) evidence
[64]
Wang S, Zhang S, Zhao L. Long-term efficacy of electrical pudendal nerve stimulation for urgency-frequency syndrome in women. International urogynecology journal. 2014 Mar:25(3):397-402. doi: 10.1007/s00192-013-2223-7. Epub 2013 Oct 3
[PubMed PMID: 24091564]
[65]
Marinkovic SP. New technologies in the management of overactive bladder: current research and future prospects. Therapeutic advances in urology. 2019 Jan-Dec:11():1756287219844669. doi: 10.1177/1756287219844669. Epub 2019 Apr 25
[PubMed PMID: 31040883]
Level 3 (low-level) evidence
[66]
Tang H, Chen J, Wang Y, Yu T, Guo C, Liao X. Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial. Urology journal. 2014 Sep 6:11(4):1800-5
[PubMed PMID: 25194079]
[67]
Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, Macdiarmid SA. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. The Journal of urology. 2010 Apr:183(4):1438-43. doi: 10.1016/j.juro.2009.12.036. Epub 2010 Feb 20
[PubMed PMID: 20171677]
Level 1 (high-level) evidence
[68]
Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. The Journal of urology. 2013 Jun:189(6):2194-201. doi: 10.1016/j.juro.2012.11.175. Epub 2012 Dec 3
[PubMed PMID: 23219541]
[69]
Tutolo M, Ammirati E, Heesakkers J, Kessler TM, Peters KM, Rashid T, Sievert KD, Spinelli M, Novara G, Van der Aa F, De Ridder D. Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature. European urology. 2018 Mar:73(3):406-418. doi: 10.1016/j.eururo.2017.11.002. Epub 2018 Jan 12
[PubMed PMID: 29336927]
Level 1 (high-level) evidence
[70]
Krhut J, Peter L, Rejchrt M, Slovak M, Skugarevska B, Zvara P. Peroneal Electric Transcutaneous NeuroModulation (eTNM(®)): A Novel Method for the Treatment of the Overactive Bladder. Journal of healthcare engineering. 2021:2021():4016346. doi: 10.1155/2021/4016346. Epub 2021 Oct 6
[PubMed PMID: 34659685]
[71]
Goudelocke C, Sobol J, Poulos D, Enemchukwu E, Zaslau S, Dhir R. A Multicenter Study Evaluating the FREquency of Use and Efficacy of a Novel Closed-Loop Wearable Tibial Neuromodulation System for Overactive Bladder and Urgency Urinary Incontinence (FREEOAB). Urology. 2024 Jan:183():63-69. doi: 10.1016/j.urology.2023.10.007. Epub 2023 Nov 7
[PubMed PMID: 37944596]
Level 2 (mid-level) evidence
[72]
Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, Vasavada SP, Nguyen JN, Wilson TS, Harvie HS, Wallace D, Pelvic Floor Disorders Network. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. European urology. 2018 Jul:74(1):66-73. doi: 10.1016/j.eururo.2018.02.011. Epub 2018 Feb 24
[PubMed PMID: 29482936]
Level 1 (high-level) evidence
[73]
Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). European urology. 2012 Sep:62(3):507-14. doi: 10.1016/j.eururo.2011.12.056. Epub 2012 Jan 5
[PubMed PMID: 22236796]
Level 1 (high-level) evidence
[74]
Harris S, Rizzolo D. Botulinum toxin as a treatment for refractory overactive bladder. JAAPA : official journal of the American Academy of Physician Assistants. 2016 Feb:29(2):1-4. doi: 10.1097/01.JAA.0000476217.57808.c4. Epub
[PubMed PMID: 26818640]
[75]
Tay LJ, Harry D, Malde S, Sahai A. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Urology. 2021 Mar:149():1-10. doi: 10.1016/j.urology.2020.11.018. Epub 2020 Nov 20
[PubMed PMID: 33227305]
[76]
Siegel S, Paszkiewicz E, Kirkpatrick C, Hinkel B, Oleson K. Sacral nerve stimulation in patients with chronic intractable pelvic pain. The Journal of urology. 2001 Nov:166(5):1742-5
[PubMed PMID: 11586214]
[77]
Laviana A, Jellison F, Kim JH. Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome. Neurosurgery clinics of North America. 2014 Jan:25(1):33-46. doi: 10.1016/j.nec.2013.08.001. Epub
[PubMed PMID: 24262898]
[78]
Sievert KD, Amend B, Gakis G, Toomey P, Badke A, Kaps HP, Stenzl A. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Annals of neurology. 2010 Jan:67(1):74-84. doi: 10.1002/ana.21814. Epub
[PubMed PMID: 20186953]
[79]
Gad PN, Kreydin E, Zhong H, Latack K, Edgerton VR. Non-invasive Neuromodulation of Spinal Cord Restores Lower Urinary Tract Function After Paralysis. Frontiers in neuroscience. 2018:12():432. doi: 10.3389/fnins.2018.00432. Epub 2018 Jun 29
[PubMed PMID: 30008661]
[80]
Keller EE, Patras I, Hutu I, Roider K, Sievert KD, Aigner L, Janetschek G, Lusuardi L, Zimmermann R, Bauer S. Early sacral neuromodulation ameliorates urinary bladder function and structure in complete spinal cord injury minipigs. Neurourology and urodynamics. 2020 Feb:39(2):586-593. doi: 10.1002/nau.24257. Epub 2019 Dec 23
[PubMed PMID: 31868966]
[81]
Redshaw JD, Lenherr SM, Elliott SP, Stoffel JT, Rosenbluth JP, Presson AP, Myers JB, Neurogenic Bladder Research Group (NBRG.org). Protocol for a randomized clinical trial investigating early sacral nerve stimulation as an adjunct to standard neurogenic bladder management following acute spinal cord injury. BMC urology. 2018 Aug 29:18(1):72. doi: 10.1186/s12894-018-0383-y. Epub 2018 Aug 29
[PubMed PMID: 30157824]
Level 1 (high-level) evidence